High-density lipoprotein-like nanoparticles with cationic cholesterol derivatives for siRNA delivery

Area of Science:

• Biotechnology
• Nanomedicine
• RNA Therapeutics

Background:

• Small interfering RNA (siRNA) holds therapeutic potential but requires effective delivery systems.
• High-density lipoprotein-like nanoparticles (HDL NPs) are being explored as carriers for nucleic acids.
• Cationic lipids (CLs) are essential components for associating siRNA with HDL NPs.

Purpose of the Study:

• To investigate a new approach for siRNA delivery using HDL NPs.
• To evaluate the efficacy of different cholesterol-derived cationic lipids (CLs) for siRNA association, cytotoxicity, and cellular uptake.
• To understand the structure-activity relationships of CLs and the influence of the phospholipid environment on HDL NP performance.

Main Methods:

• Synthesis and testing of novel and commercial CLs, including GL67 and DC-Cholesterol.
• Assessment of siRNA binding efficiency, cytotoxicity, and cellular uptake in HepG2 cells.
• Analysis of the impact of CL head group structure and phospholipid environment on HDL NP functionality.

Main Results:

• GL67 demonstrated significant siRNA uptake and cytosolic delivery in HepG2 cells.
• Gene silencing efficiency with GL67-loaded HDL NPs was limited, indicating a need for optimization.
• CL head group structure, linker type, and alkyl chain length critically influence HDL NP performance.
• The phospholipid environment significantly affects siRNA cellular uptake by HDL NPs.
• Intracellular siRNA trafficking is cell-type dependent, necessitating tailored HDL NP formulations.

Conclusions:

• Positively charged cholesterol derivatives, particularly GL67, show potential for siRNA delivery via HDL NPs.
• Optimization of CL design and the phospholipid environment is crucial for enhancing gene silencing.
• Customizing HDL NP formulations for specific cell types is essential for effective siRNA therapeutic delivery.